Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-705 alone or in combination for HER2-expressing advanced malignant solid tumors
CTR20252338Phase 2Active
- Sponsor
- 3SBio
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-705 in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC), sponsored by 3SBio. Started Jun 2025; status: active.
02
Drugs
SSGJ-705
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252338.